

13.08.2014

VRL/SEC/NSE

National Stock Exchange of India Ltd.
5th Floor , Exchange Plaza
Bandra (E),
Mumbai- 400 051

Sub.: Outcome of Board Meeting

This is to inform you that, the Board of Directors of the Company at its meeting held today considered and approved Unaudited Financial Results(Provisional) for the quarter ended 30.06.2014

Thanking you.

Yours faithfully,
for VENUS REMEDIES LIMITED.


Neha Kodan
(Company Secretary)



VENUS REMEDIES LIMITED

CIN-L24232CH1989PLC009705

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com



Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368, Werne, Germany

13.08.2014

VRL/SEC/NSE

National Stock Exchange of India Ltd.
5th Floor , Exchange Plaza
Bandra (E),
Mumbai- 400 051

Sub.: Submission of Unaudited Financial Results

Dear Sir/Madam,

Please find enclosed herewith copy of Unaudited Financial Results(Provisional) for the quarter ended 30.06.2014 which were taken on record by the Board of Directors at its meeting held on 13.08.2014

Kindly acknowledge the receipt.

Thanking you.

Yours faithfully,
for VENUS REMEDIES LIMITED


Neha Kodan
(Company Secretary)



VENUS REMEDIES LIMITED

CIN-L24232CH1369FLC009705

Corporate Office :
51-52, Industrial Area, Phase-I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com



Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jhamajri EPB Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
Am Bahnhof 1-3, D-59368, Werne, Germany

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL)
FOR THE QUARTER ENDED 30th June, 2014**

(Rs. in millions)

S. No.	Part - I PARTICULARS	Quarter Ended on		Year Ended	
		30/06/2014	31/03/2014	30/06/2013	31/03/2014
		Unaudited	Audited	Unaudited	Audited
1	Net Sales/ Income from operations	1210.55	1375.11	1268.79	5195.44
	Gross Sales	2.42	2.17	2.34	8.54
	Less - Excise Duty	1208.13	1372.94	1266.45	5186.9
	(a) Net Sales	6.66	50.49	5.63	73.65
	(b) Other Operating Income				
	Total Income from Operation (Net)	1,214.79	1,423.43	1,272.08	5,260.55
2	Expenses	829.42	853.78	752.50	3,012.81
	(a) Consumption of raw materials	49.12	(35.4)	(2.80)	(23.22)
	(b) (Increase)/ Decrease in stock in trade	63.42	76.87	59.17	255.65
	(c) Employee benefits expense	111.30	96.70	95.35	386.09
	(d) Depreciation & amortization expense	176.45	194.01	147.14	883.03
	(e) Other expenses	1,034.16	1,185.96	1,051.36	4,314.36
	Total expense	180.63	237.47	220.72	946.19
3	Profit from operations before other income, finance costs and exceptional items (1-2)	291.93	334.17	316.07	1,332.28
	EBIDTA (3+2(d))	1.00	1.92	8.18	4.06
4	Other income	181.63	239.39	228.90	950.25
5	Profit before finance costs and exceptional items (3+4)	83.59	73.48	66.81	292.93
6	Finance Costs	98.04	165.91	162.09	657.32
7	Profit after finance costs but before exceptional items (5-6)	0.00	0.00	0.00	0.00
8	Exceptional items	98.04	165.91	162.09	657.32
9	Profit from ordinary activities before tax (7+8)	0.00	24.82	08.97	47.82
10	Tax expense	102.49	141.09	153.12	609.50
11	Profit from ordinary activities after tax (9-10)	00.00	0.00	0.00	0.00
12	Exceptional items (net of tax expense)	102.49	141.09	153.12	609.50
13	Net profit for the period (11-12)	114.42	114.42	114.42	114.42
14	Paid up Equity Share Capital	N. A.	N. A.	N. A.	4,520.26
15	Reserves excluding revaluation reserves	8.96	12.33	13.38	54.19
16	E.P.S - Basic not annualized for the qtr	35.83	49.32	53.53	54.19
	- Annualized				
Part - II					
1	Public Shareholding	7154551	6437086	6437086	6437086
	- Number of Shares	62.53	56.26	56.26	56.26
	- Percentage of Shareholding				
2	Promoters and promoter group shareholding				
a)	Pledged as collateral security to bank	1937250	2080000	1930000	2080000
	- Number of Shares	45.18	41.56	38.56	41.56
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	16.93	18.18	16.87	18.18
	- Percentage of shares (as a % of the total share capital				
b)	Non-Encumbered	2350187	2924902	3074902	2924902
	- Number of Shares	54.82	58.44	61.44	58.44
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	20.54	25.56	26.87	25.56
	- Percentage of shares (as a % of the total share capital				
Particulars		Quarter ended 30.06.2014			
(B) INVESTOR COMPLAINTS		1			
Pending at the beginning of the quarter		NIL			
Received during the quarter		1			
Disposed of during the quarter		NIL			
Remaining unresolved at the end of the quarter		NIL			

CIN-L24232CH1989PLC009705

For VENUS REMEDIES LIMITED
CHAIRMAN & MANAGING DIRECTOR

Notes:

1. The above financial Results were reviewed by the Audit Committee and taken on record at the Board Meeting on August 13, 2014.
2. During the Quarter:
 - a) Venus Remedies gets marketing nod from Venezuela for meropenem
 - b) Venus Remedies bags Market Authorization of Meropenem Injection from, TGA, Australia
 - c) Venus Remedies bags additional patent for Vancoplus from US
 - d) VMRC Drug VRP008 to Fight "MULTI-DRUG Resistant Bacteria" Received European Patent
3. Investor Complaints pending during the beginning of the quarter-1, Received during the quarter-NIL, Disposed of during the quarter-NIL, Remaining unresolved at the end of the quarter-NIL
4. The Company caters to only one segment i.e. "Pharmaceutical Formulations".

**For and on behalf of Board of Directors
For VENUS REMEDIES LIMITED**



(Pawan Chaudhary)

Chairman & Managing Director

Date : 13.08.2014